title: Functional analysis of a mutation occurring between the two in-frame AUG codons of human angiotensinogen.
abstract: Angiotensinogen (ANG) is the specific substrate of the renin-angiotensin system, a major participant in blood pressure control. We have identified a natural mutation at the -30 amino acid position of the angiotensinogen signal peptide, in which an arginine is replaced by a proline (R-30P). Heterozygous individuals with R-30P showed a tendency to lowered plasma angiotensinogen level (1563 ng of ANG I/ml (range 1129-1941)) compared with normal individuals in the family (1892 ng of ANG I/ml (range 1603-2072)). Human angiotensinogen mRNA has two in-phase translation initiation codons (AUG) starting upstream 39 and 66 nucleotides from the cap site. R-30P occurs in a cluster of basic residues adjacent to the first AUG codon that may affect intracellular sorting of the nascent protein. Pulse-chase experiments in transiently transfected cultured cells revealed that the R-30P mutation was associated with reduced amounts of both intra- and extracellular protein. In a cell-free system, we found that two forms of native angiotensinogen were generated by alternative initiation of translation at either AUG codon. Alteration of either the first or second AUG codons abolished the synthesis of the longer and the shorter form of native angiotensinogen, respectively. Furthermore, the rate of secretion of the shorter form was lower than that of the longer form. By transplanting angiotensinogen signal peptide onto green fluorescence protein, however, we found that both forms of the signal peptide could target green fluorescence protein, normally localized in the cytoplasm, to the secretory pathway. Although the R-30P mutation may not affect intracellular sorting of angiotensinogen in a qualitative manner, it leads to a quantitative reduction in the net secretion of mature angiotensinogen through decreased translocation or increased residence time in the endoplasmic reticulum.
authors.affiliation: Howard Hughes Medical Institute, University of Utah Health Sciences Center, Salt Lake City, Utah 84112, USA.
authors.forename: T
authors.initials: T
authors.lastname: Nakajima
authors.forename: T
authors.initials: T
authors.lastname: Cheng
authors.forename: A
authors.initials: A
authors.lastname: Rohrwasser
authors.forename: L J
authors.initials: LJ
authors.lastname: Bloem
authors.forename: J H
authors.initials: JH
authors.lastname: Pratt
authors.forename: I
authors.initials: I
authors.lastname: Inoue
authors.forename: J M
authors.initials: JM
authors.lastname: Lalouel
mesh_terms: D000595:Amino Acid Sequence; D000808:Angiotensinogen / Q000737:chemistry / Q000235:genetics*; D000818:Animals; D001483:Base Sequence; D019556:COS Cells; D003062:Codon / Q000235:genetics; D005260:Female; D006801:Humans; D006973:Hypertension / Q000235:genetics*; D008297:Male; D008969:Molecular Sequence Data; D010375:Pedigree; D017354:Point Mutation; D018807:Polymorphism, Single-Stranded Conformational; D014176:Protein Biosynthesis; D012333:RNA, Messenger / Q000235:genetics; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry; D014162:Transfection
chemical_list: D003062:Codon; D012333:RNA, Messenger; D011994:Recombinant Proteins; D000808:Angiotensinogen